Who Paid My Doc
Zoheir Abdelbaki
Nuclear Cardiology Lima, OH Medical Doctor
NPI 1396818571 CMS profile 199022
730 W Market St, 2K Tower, Lima, OH 45801
General payments
$5,708
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Zoheir Abdelbaki of Lima, OH is reported in the CMS Open Payments database as having received $5,708 across 365 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 67th percentile of Nuclear Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $146 | 8 | |
| 2024 | General | $345 | 23 | |
| 2023 | General | $649 | 40 | |
| 2022 | General | $981 | 71 | |
| 2021 | General | $1,059 | 80 | |
| 2020 | General | $1,243 | 67 | |
| 2019 | General | $1,285 | 76 |
Beside peers
- Zoheir Abdelbaki
- Nuclear Cardiology median
- Middle half of Nuclear Cardiology
- National median
In program year 2025, general payments to Zoheir Abdelbaki were reported at $146. Among 99 Nuclear Cardiology profiles paid that year, the median was $434 and the middle half received between $138 and $985.
Show as a table
| Year | Zoheir Abdelbaki | Nuclear Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,285 | $552 | $91–$1,768 | $163 |
| 2020 | $1,243 | $204 | $61–$1,106 | $114 |
| 2021 | $1,059 | $354 | $99–$886 | $132 |
| 2022 | $981 | $506 | $101–$1,186 | $149 |
| 2023 | $649 | $545 | $148–$1,432 | $160 |
| 2024 | $345 | $484 | $131–$1,430 | $164 |
| 2025 | $146 | $434 | $138–$985 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 83 drugsPart D claims
23,036
Drug cost
$4,483,466
Branded share of claims
30.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 1,962 | $2,409,272 | |
| Xarelto Rivaroxaban | Brand | 461 | $537,964 | |
| Entresto Sacubitril/Valsartan | Brand | 260 | $391,860 | |
| Repatha Sureclick Evolocumab | Brand | 182 | $264,602 | |
| Brilinta Ticagrelor | Brand | 240 | $207,363 | |
| Praluent Pen Alirocumab | Brand | 69 | $93,134 | |
| Droxidopa | Generic | 29 | $76,050 | |
| Jardiance Empagliflozin | Brand | 51 | $72,990 | |
| Metoprolol Succinate | Generic | 2,351 | $36,941 | |
| Farxiga Dapagliflozin Propanediol | Brand | 34 | $35,991 |
The 10 drugs with the highest cost, of 83 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 53 billing codesPaid by Medicare
$464,358
Medicare patients
4,475
Services billed
13,372
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 59% | |
| Arthritis | 56% | |
| Diabetes | 40% | |
| Heart failure | 38% | |
| Atrial fibrillation | 36% | |
| Chronic kidney disease | 36% | |
| Depression | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
365 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nuclear Cardiology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Nuclear Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.